Amedeo Smart

Free Medical Literature Service

 

Amedeo

Poisoning
  Free Subscription

Articles published in
J Hepatol
    September 2023
  1. UZUN S, Zinner CP, Beenen AC, Alborelli I, et al
    Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics.
    J Hepatol. 2023;79:666-676.
    >> Share

    August 2023
  2. ROMA K, Mohammed S, Sieck B, Naik K, et al
    Kratom-induced acute liver injury: A case study and the importance of herbal supplement regulation.
    J Hepatol. 2023;79:581-584.
    >> Share

    May 2023
  3. ANDRADE RJ, Aithal GP, de Boer YS, Liberal R, et al
    Nomenclature, Diagnosis and Management of Drug-induced Autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.
    J Hepatol. 2023 May 8:S0168-8278(23)00320-3. doi: 10.1016/j.jhep.2023.
    >> Share

  4. ZHANG CJ, Meyer SR, O'Meara MJ, Huang S, et al
    A human liver organoid screening platform for DILI risk prediction.
    J Hepatol. 2023;78:998-1006.
    >> Share

  5. DALY AK, Bjornsson ES, Lucena MI, Andrade RJ, et al
    Drug-induced liver injury due to nitrofurantoin: Similar clinical features, but different HLA risk alleles in an independent cohort.
    J Hepatol. 2023;78:e165-e166.
    >> Share

    March 2023
  6. JAGADISAN B, Dhawan A
    Multidisciplinary approach and reactive immunosuppression for gene therapy related hepatotoxicity.
    J Hepatol. 2023 Mar 28:S0168-8278(23)00197-6. doi: 10.1016/j.jhep.2023.
    >> Share

  7. NOGUEIRAS R, Aspichueta P
    Expanding the roles of the renin-angiotensin system: Drug-induced liver injury.
    J Hepatol. 2023;78:457-459.
    >> Share

    February 2023
  8. CHALASANI N, Li YJ, Dellinger A, Navarro V, et al
    Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury.
    J Hepatol. 2023;78:293-300.
    >> Share

    November 2022
  9. CHEN S, Lu Z, Jia H, Yang B, et al
    Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice.
    J Hepatol. 2022 Nov 9. pii: S0168-8278(22)03285.
    >> Share

    August 2022
  10. BLACK SM, Zhang Z, Han Y, Zeng C, et al
    Reply to: "Protection against acetaminophen-induced liver injury with MG53: Muscle-liver axis and necroptosis".
    J Hepatol. 2022;77:562-563.
    >> Share

  11. BJORNSSON HK, Bjornsson ES
    Reply to: "Can azathioprine prevent infliximab-induced liver injury?"
    J Hepatol. 2022;77:555-556.
    >> Share

  12. JAESCHKE H, Umbaugh DS
    Protection against acetaminophen-induced liver injury with MG53: Muscle-liver axis and necroptosis.
    J Hepatol. 2022;77:560-562.
    >> Share

  13. MEUNIER L, Malezieux E, Bozon A, Meszaros M, et al
    Can azathioprine prevent infliximab-induced liver injury?
    J Hepatol. 2022;77:553-555.
    >> Share

    May 2022
  14. AHMAD J, Barnhart HX, Bonacini M, Ghabril M, et al
    Value of liver biopsy in the diagnosis of drug-induced liver injury.
    J Hepatol. 2022;76:1070-1078.
    >> Share

    April 2022
  15. CHALASANI N, Bonkovsky HL, Stine JG, Gu J, et al
    Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
    J Hepatol. 2022;76:832-840.
    >> Share

    March 2022
  16. XU L, Yang Y, Wen Y, Jeong JM, et al
    Hepatic recruitment of eosinophils and their protective function during acute liver injury.
    J Hepatol. 2022 Mar 5. pii: S0168-8278(22)00131.
    >> Share

    February 2022
  17. GHALLAB A, Hassan R, Hofmann U, Friebel A, et al
    Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity.
    J Hepatol. 2022 Feb 4. pii: S0168-8278(22)00062.
    >> Share

  18. BJORNSSON ES, Andrade RJ
    Long-term sequelae of drug-induced liver injury.
    J Hepatol. 2022;76:435-445.
    >> Share

    January 2022
  19. SHROFF H, Satapathy SK, Crawford JM, Todd NJ, et al
    Liver injury following SARS-CoV-2 vaccination: A multicenter case series.
    J Hepatol. 2022;76:211-214.
    >> Share

  20. BJORNSSON HK, Gudbjornsson B, Bjornsson ES
    Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.
    J Hepatol. 2022;76:86-92.
    >> Share

    November 2021
  21. HAN Y, Black S, Gong Z, Chen Z, et al
    Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injury.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02154.
    >> Share

    October 2021
  22. FERNANDEZ-CHECA JC, Bagnaninchi P, Ye H, Sancho-Bru P, et al
    Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET].
    J Hepatol. 2021;75:935-959.
    >> Share

    August 2021
  23. TAVABIE OD, Karvellas CJ, Salehi S, Speiser JL, et al
    A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure.
    J Hepatol. 2021;75:424-434.
    >> Share

  24. ASHBY K, Zhuang W, Gonzalez-Jimenez A, Alvarez-Alvarez I, et al
    Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI.
    J Hepatol. 2021;75:333-341.
    >> Share

    July 2021
  25. STEPHENS C, Robles-Diaz M, Medina-Caliz I, Garcia-Cortes M, et al
    Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.
    J Hepatol. 2021;75:86-97.
    >> Share

    March 2021
  26. MOZZANEGA B
    Ulipristal acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya.
    J Hepatol. 2021;74:750-751.
    >> Share

  27. CHAND D, Mohr F, McMillan H, Tukov FF, et al
    Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
    J Hepatol. 2021;74:560-566.
    >> Share

    February 2021
  28. GUDD CL, Au L, Triantafyllou E, Shum B, et al
    Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis.
    J Hepatol. 2021 Feb 22. pii: S0168-8278(21)00108.
    >> Share

  29. LIEBE R, Esposito I, Bock HH, Dahl SV, et al
    Diagnosis and management of secondary causes of steatohepatitis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00096.
    >> Share

    May 2020
  30. STATTERMAYER AF, Halilbasic E, Wrba F, Ferenci P, et al
    Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30280.
    >> Share

    February 2019
  31. MANCO R, Clerbaux LA, Verhulst S, Nader MB, et al
    Reactive cholangiocytes differentiate into proliferative hepatocytes with efficient DNA repair in mice with chronic liver injury.
    J Hepatol. 2019 Feb 19. pii: S0168-8278(19)30117.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016